Hope for rare brain disorder: new drug trial targets Jordan's syndrome
NCT ID NCT06717438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called zatolmilast in 30 people aged 9 to 45 with Jordan's Syndrome, a rare genetic disorder affecting brain development. The goal is to see if the drug improves language and communication skills and is safe. Participants take the drug or a placebo for 24 weeks, and researchers monitor side effects and changes in symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JORDAN'S SYNDROME are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Seattle Children's Hospital
Seattle, Washington, 98101, United States